Cotinine effects on nicotine metabolism.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Cotinine is the major primary metabolite of nicotine, and it accumulates in the body with regular smoking.

Nicotine and cotinine appear to be metabolized by the same liver enzyme.

Who Took Part

The study group was 12 volunteers.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The subjects were 12 healthy nonsmoking volunteers.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the volunteers nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

In the crossover set-up each of the volunteers took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

This was a crossover, randomized, double-blind, and placebo-controlled study.

What Was Measured

Cotinine is the major primary metabolite of nicotine, and it accumulates in the body with regular smoking.

The subject headings attached to it are Cotinine, Half-Life, Nicotine and Nicotinic Agonists.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 12 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.